Sundance Dx Licenses Markers from Max Planck for Suicide Risk Test | GenomeWeb

NEW YORK (GenomeWeb News) – Sundance Diagnostics today announced an exclusive, worldwide licensing deal with the Max Planck Institute of Psychiatry aimed at developing and commercializing a genetic test for predicting the risk of suicide from use of antidepressants.

Sundance will validate and commercialize the test, which is based on a set of biomarkers discovered by researchers at Max Planck. The Boulder, Colo.-based company plans to launch the test as a laboratory-developed test in the US and Europe and will provide an update on its availability in early 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.